Vitamin C for COVID-19: A living systematic review

Simple item page
dc.catalogadorjlo
dc.contributor.authorBaladia, Eduard
dc.contributor.authorPizarro, Ana Beatriz
dc.contributor.authorOrtiz Muñoz, Luis Eugenio
dc.contributor.authorRada Giacaman, Gabriel Alejandro
dc.date.accessioned2024-06-25T20:47:33Z
dc.date.available2024-06-25T20:47:33Z
dc.date.issued2020
dc.description.abstractObjective: This living systematic review aims to provide a timely, rigorous, and continuously updated summary of the available evidence on the role of vitamin C in treating patients with COVID-19.Data sources: We conducted searches in PubMed/MEDLINE, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature, and in a centralized repository in L·OVE (Living OVerview of Evidence). In response to the COVID-19 emergency, L·OVE was adapted to expand the range of evidence it comprises and has been customized to group all COVID-19 evidence in one place. All the searches covered the period until April 29, 2020 (one day before submission).Study selection and methods: We adapted an already published standard protocol for multiple parallel systematic reviews. We searched for randomized trials evaluating the effect, in patients with COVID-19, of vitamin C versus placebo or no treatment. Anticipating the lack of randomized trials directly addressing this question, we also searched for trials evaluating MERS-CoV and SARS-CoV, and non-randomized studies in COVID-19. Two reviewers independently screened each study for eligibility. A living, web-based version of this review will be openly available during the COVID-19 pandemic, and we will resubmit it to the journal whenever there are substantial updates.Results: We screened 95 records, but no study was considered eligible. We identified 20 ongoing studies, including 13 randomized trials evaluating vitamin C in COVID-19.Conclusions: We did not find any studies that met our inclusion criteria, and hence there is no evidence to support or refute the use of vitamin C in the treatment of patients with COVID-19. A substantial number of ongoing studies should provide valuable evidence to inform researchers and decision-makers soon.
dc.format.extent8 páginas
dc.fuente.origenConveris
dc.identifier.doi10.5867/medwave.2020.06.7978
dc.identifier.issn0717-6384
dc.identifier.scopusidSCOPUS_ID:2-s2.0-85089170531
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/86854
dc.information.autorucEscuela de Medicina; Ortiz Muñoz, Luis Eugenio; 0000-0001-6449-2153; 121678
dc.information.autorucEscuela de Medicina; Rada Giacaman, Gabriel Alejandro; 0000-0003-2435-0710; 11470
dc.issue.numero6
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final8
dc.pagina.inicio1
dc.revistaMedwave
dc.rightsacceso restringido
dc.subjectAscorbic acid
dc.subjectCoronavirus infections
dc.subjectCoronavirus disease
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleVitamin C for COVID-19: A living systematic review
dc.typeartículo
dc.volumen20
sipa.codpersvinculados121678
sipa.codpersvinculados11470
sipa.trazabilidadConveris;20-07-2021
Files
Collections
Artículos de revistas